A Korea Consumer Agency (KCA) survey has revealed that 16 dietary supplements marketed with claims of mimicking the effects of GLP-1 receptor agonists – a class of drugs including Ozempic and Wegovy used for weight management – contain ingredients that do not effectively deliver those benefits. The findings, released Tuesday, highlight misleading advertising practices targeting consumers seeking weight loss solutions.
The KCA’s investigation focused on products advertised as offering similar metabolic effects to prescription GLP-1 medications. These products, often available in drinkable or capsule form, frequently employ marketing language suggesting they can aid in appetite suppression and fat reduction. However, the agency found that many contained only vitamins, minerals, or herbal extracts in quantities insufficient to replicate the physiological actions of GLP-1 agonists.
The surge in demand for GLP-1 medications, initially prescribed for type 2 diabetes, has been driven by their observed weight loss side effects. This demand has, in turn, fueled a parallel market of over-the-counter supplements promising similar results. The KCA’s report indicates that manufacturers are capitalizing on this trend with products lacking scientific backing.
The findings come as Ozempic is set to gain coverage under South Korea’s national health insurance, albeit with strict conditions, according to a recent report by NAVLIN DAILY. This expansion of coverage is expected to increase access to the legitimate medication for patients with diabetes, but also potentially exacerbate the demand and the market for unproven alternatives.
patent protection for Ozempic is slated to begin expiring in 2026, as reported by czapp.com. This expiration is anticipated to open the door for generic versions of the drug, potentially lowering costs and increasing competition. However, it also raises questions about the future landscape of GLP-1 therapies and the potential for further proliferation of unregulated products.
Concurrent with the domestic supplement concerns, global licensing deals for pre-approval Korean assets have surged, according to NAVLIN DAILY. While not directly related to the GLP-1 supplement issue, this trend suggests a broader increase in investment and activity within the Korean pharmaceutical and biotechnology sectors.
The KCA has not yet announced specific enforcement actions related to the misleading supplement advertisements. The agency’s report does not detail which companies are producing the ineffective products, nor does it specify the penalties that may be imposed. The KCA has indicated it will share its findings with relevant regulatory bodies for further review and potential legal action.
